Travere Therapeutics, Inc. TVTX Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s investment proceeds?
- Travere Therapeutics, Inc. (TVTX) reported investment proceeds of $48.78M in Q1 2026.
- How has Travere Therapeutics, Inc.'s investment proceeds changed year-over-year?
- Travere Therapeutics, Inc.'s investment proceeds decreased by 8.2% year-over-year, from $53.16M to $48.78M.
- What is the long-term trend for Travere Therapeutics, Inc.'s investment proceeds?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s investment proceeds has grown at a -7.1% compound annual growth rate (CAGR), from $433.6M to $323.6M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.